912
Participants
Start Date
December 4, 2012
Primary Completion Date
May 13, 2015
Study Completion Date
July 30, 2015
ASP1707
Oral
Placebo
Oral
Leuprorelin acetate
subcutaneous
Site: 1104, Sofia
Site: 1401, Budapest
Site: 1006, Brussels
Site: 1107, Sofia
Site: 1106, Sofia
Site: 1001, Leuven
Site: 1002, Genk
Site: 1005, Liège
Site: 1408, Debrecen
Site: 1103, Stara Zagora
Site: 1422, Kecskemét
Site: 1403, Szekszárd
Site: 1003, Ghent
Site: 1602, Bucharest
Site: 2003, Tokyo
Site: 1105, Plovdiv
Site: 1102, Sofia
Site: 1390, Berlin
Site: 1304, Dresden
Site: 1302, Erlangen
Site: 1311, Karlsruhe
Site: 1306, Lübeck
Site: 1407, Budapest
Site: 1406, Pécs
Site: 1402, Székesfehérvár
Site: 2039, Hyōgo
Site: 2040, Hyōgo
Site: 2032, Kagoshima
Site: 2035, Kanagawa
Site: 2036, Nagano
Site: 2037, Nagano
Site: 2038, Nagano
Site: 2016, Tokyo
Site: 1505, Bialystok
Site: 1512, Gdansk
Site: 1509, Warsaw
Site: 1525, Warzawa
Site: 1604, Brasov
Site: 1607, Bucaresti
Site: 1601, Bucharest
Site: 1606, Bucharest
Site: 1603, Târgu Mureş
Site: 1701, Bucuresti
Site: 1702, Bucuresti
Site: 1705, Bucuresti
Site: 1707, Bucuresti
Site: 1713, Donetsk
Site: 1716, Donetsk
Site: 1708, Kyiv
Site: 1703, Targu Mures
Site: 1717, Zaporizhzhya
Site: 2018, Aomori
Site: 2017, Chiba
Site: 2005, Fujisawa
Site: 2034, Hyōgo
Site: 2015, Kanagawa
Site: 2013, Kawagoe
Site: 2029, Kawasaki
Site: 2024, Kawasaki
Site: 2033, Kochi
Site: 2031, Kumamoto
Site: 2010, Kurashiki
Site: 2006, Kyoto
Site: 2002, Nagaoka
Site: 2007, Nagasaki
Site: 2011, Nara
Site: 2027, Sapporo
Site: 2001, Sapporo
Site: 2030, Sapporo
Site: 2004, Tokyo
Site: 2020, Tokyo
Site: 2014, Tokyo
Site: 2009, Tokyo
Site: 2028, Tokyo
Site: 2025, Tokyo
Site: 2012, Yokohama
Site: 1501, Bialystok
Site: 1504, Katowice
Site: 1508, Lublin
Site: 1507, Lublin
Site: 1502, Warsaw
Site: 1807, London
Site: 1804, Norwich
Site: 1808, Sheffield
Site: 1806, Southampton
Astellas Pharma Europe B.V.
INDUSTRY